InMed Pharmaceuticals

Company Name: InMed Pharmaceuticals

Company Website:

Contact Name: Josh Blacher

Contact Email:

What is your company's primary cannabis business?: Manufacturing

Does your company touch the plant?: No

Company's Bio (Pitch Deck): InMed is a biopharmaceutical company that specializes in the discovery and development of novel, cannabinoid-based therapeutics for the treatment of diseases with high unmet medical need.

InMed employs a highly scientific approach to designing and developing medicines, which will help unlock the full potential of cannabinoid pharmaceuticals. One proprietary technology is our bioinformatics platform, which uses a computer-based drug candidate selection process to reach high-probability conclusions from massive, publicly available databases together with an internal library of cannabinoid drug information.

InMed is also developing a robust, high-yield, microbial-based biosynthesis process designed to enable the manufacturing of the multitude of cannabinoids (90+) found from natural sources. InMed products are designed to be bio-identical to the naturally-occurring cannabinoids and the process envisioned to offer cost and time savings, and superior ease, control and quality of manufacturing when compared to alternative methods.

C-Suite Bio's (Pitch Deck): Eric A. Adams, MIBS
Chief Executive Officer & President

Eric A. Adams was appointed Chief Executive Officer, President and Director of InMed Pharmaceuticals, Inc. in June 2016. During his tenure at InMed, he has reconstituted the Board of Directors and the Executive management team and has raised more than $35M in

capital to fund operations. Mr. Adams is a seasoned biopharmaceutical executive with over 25 years’ experience in establishing corporate entities, capital formation, global market development, mergers & acquisitions, licensing and corporate governance.

Mr. Adams previously served as CEO at enGene Inc., where he oversaw its transformation from a nascent start-up into a venture capital-backed leader in gene therapy. Prior to enGene, Mr. Adams held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL), and Fresenius AG (Germany). As the previous Chairman of BIOTECanada’s Emerging Company Advisory Board, and for his extensive generosity in mentoring biotech entrepreneurs, Mr. Adams is well respected within the Canadian biotech industry as a strategic advisor to a number of early-stage biotech companies. 

He is a dual citizen of Canada and the United States, and holds a Masters of International Business from the University of South Carolina and a Bachelor’s Degree in Chemistry from the University of Southern Indiana.

Josh Blacher, MBA
Chief Business Officer

Mr. Blacher joined InMed Pharmaceuticals in 2018, bringing two decades of leadership experience in senior positions within the US healthcare and capital markets sectors, focusing primarily on strategic finance, business development, and managing relations with

the investment community. 

Before joining InMed, Mr. Blacher served as Chief Financial Officer at Therapix Biosciences (NASDAQ:TRPX) and Galmed Pharmaceuticals (NASDAQ:GLMD). Previously, Mr. Blacher also held senior positions in licensing and investing at Teva Pharmaceuticals, portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in Mergers & Acquisitions at Lehman Brothers. 

Mr. Blacher holds an MBA in Finance from Columbia Business School.

Dr. Sazzad Hossain, PhD, MSc
Chief Scientific Officer 

Dr. Hossain has more than 20 years of academic and industrial experience in new drug discovery and natural health product development. His experience in phytochemistry and drug development served as the scientific foundation of InMed. As Group Leader and

Senior Scientist at Biotechnology Research Institute of National Research Council Canada, of the Canadian Government primary biotechnology research organization, he established a pharmacology laboratory to evaluate the safety and efficacy of new drugs under development for the treatment of cancer, cardiovascular and ocular diseases. 

Prior to joining the National Research Council Canada, he served as Associate Director of Pharmacology at Xenon Pharmaceuticals in Vancouver, B.C., leading pharmacology teams targeting pain, inflammation and cardiovascular diseases. Dr. Hossain received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of The University of British Columbia. He served as Associate Professor of Pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996, and is the author of more than 40 peer-reviewed papers; primarily in the fields of pharmacology, genetics and nutritional sciences.

Social Media Handles:

  • Twitter - @InMedPharma

  • LinkedIn  - InMed Pharmaceuticals

  • Facebook - @InMedPharma


Dan Humiston